UNSPSC 51152061: Lanperisone hydrochloride

This classification denotes a muscle relaxant with the molecular formula C15H18F3NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JRF22NV56M, chemically known as (-)-lanperisone hydrochloride, but more generally known as lanperisone hydrochloride, which bears US NIH Compound Identifier 198706. European Medicines Agency schedules lanperisone hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08400MIG.

Most nations, for tariff purposes, schedule lanperisone hydrochloride under HS 29339990. SMILES: C[C@H](CN1CCCC1)C(=O)C2CCC(CC2)C(F)(F)F.CL.

UNSPSC 51152061 Lanperisone hydrochloride is a Commodity code representing a specific pharmaceutical agent, but the recent state and local opportunities tagged under it do not reflect procurement of lanperisone itself. Instead, the tagged solicitations address naloxone procurement and direct-to-manufacturer pharmacy benefit programs — products and services outside the scope of this code's nominal definition. Seminole County, Florida issued IFB 60459723LAS seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to its Community Health Building and a two-year contract term plus one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 to gather vendor intelligence on establishing direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers, seeking responses on April 3, 2026, to inform future procurement strategy around therapeutic pharmacy initiatives and direct-to-manufacturer prescription fulfillment models. These opportunities reflect state and local investment in opioid-overdose response infrastructure and pharmacy cost-management innovation rather than procurement of lanperisone hydrochloride as a muscle relaxant pharmaceutical.

The geographic activity visible under this code spans Florida and Texas, though the mismatch between the code's nominal scope and the actual work being solicited suggests minimal relevant recent procurement activity for lanperisone itself. Seminole County's naloxone bid, due July 26, 2023, required electronic submission through the county e-Procurement Portal, drug-free workplace certification, and E-Verify compliance, with fixed-fee pricing and potential FEMA funding. The Texas HHS RFI represents early-stage market research rather than a committed procurement vehicle, with no award value, budget range, or formal evaluation criteria specified at the time of posting. Vendors pursuing this code should verify that state and local health agencies, public safety departments, and human services commissions are actually buying lanperisone under separate solicitations, as the recent opportunities on record do not demonstrate active demand for this specific pharmaceutical product.